165 related articles for article (PubMed ID: 36943511)
21. Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma.
Rini BI; Signoretti S; Choueiri TK; McDermott DF; Motzer RJ; George S; Powles T; Donskov F; Tykodi SS; Pal SK; Gupta S; Lee CW; Jiang R; Tannir NM
J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36549781
[TBL] [Abstract][Full Text] [Related]
22. Quality-Adjusted Time without Symptoms or Toxicity: Analysis of Axicabtagene Ciloleucel versus Standard of Care in Patients with Relapsed/Refractory Large B Cell Lymphoma.
Kersten MJ; Qiao Y; Shah R; Solem C; Snider JT; To C; Cheng P; Spooner C; Perales MA
Transplant Cell Ther; 2023 May; 29(5):335.e1-335.e8. PubMed ID: 36646322
[TBL] [Abstract][Full Text] [Related]
23. Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: Analysis of Number Needed To Treat and Number Needed To Harm.
Sugarman R; Betts KA; Nie X; Hartman J; Nguyen H
Clin Ther; 2023 Nov; 45(11):1155-1158. PubMed ID: 37748935
[TBL] [Abstract][Full Text] [Related]
24. Cost-effectiveness analysis of nivolumab plus ipilimumab plus two cycles of platinum-doublet chemotherapy versus platinum-doublet chemotherapy alone for first-line treatment of stage IV or recurrent non-small cell lung cancer in the United States.
Polyzoi M; Sandhu H; Maervoet J; Yuan Y; Chaudhary MA; Varol N; Lee A; Dale P; Jones C; Lubinga SJ; Penrod JR
J Med Econ; 2022; 25(1):660-668. PubMed ID: 35658806
[TBL] [Abstract][Full Text] [Related]
25. Cost-utility of sintilimab plus chemotherapy vs chemotherapy as first-line treatment of advanced gastric or gastroesophageal junction cancer in China.
Li W; Wan L
Expert Rev Pharmacoecon Outcomes Res; 2024 Jun; 24(5):671-678. PubMed ID: 38594905
[TBL] [Abstract][Full Text] [Related]
26. Long-term comparative efficacy and safety of nivolumab plus ipilimumab relative to other first-line therapies for advanced non-small-cell lung cancer: A systematic literature review and network meta-analysis.
O'Byrne K; Popoff E; Badin F; Lee A; Yuan Y; Lozano-Ortega G; Eccles LJ; Varol N; Waser N; Penrod JR; Goring S
Lung Cancer; 2023 Mar; 177():11-20. PubMed ID: 36669321
[TBL] [Abstract][Full Text] [Related]
27. Quality-adjusted survival with combination nab-paclitaxel + gemcitabine vs gemcitabine alone in metastatic pancreatic cancer: a Q-TWiST analysis.
Reni M; Wan Y; Solem C; Whiting S; Ji X; Botteman M
J Med Econ; 2014 May; 17(5):338-46. PubMed ID: 24654922
[TBL] [Abstract][Full Text] [Related]
28. Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma.
Doki Y; Ajani JA; Kato K; Xu J; Wyrwicz L; Motoyama S; Ogata T; Kawakami H; Hsu CH; Adenis A; El Hajbi F; Di Bartolomeo M; Braghiroli MI; Holtved E; Ostoich SA; Kim HR; Ueno M; Mansoor W; Yang WC; Liu T; Bridgewater J; Makino T; Xynos I; Liu X; Lei M; Kondo K; Patel A; Gricar J; Chau I; Kitagawa Y;
N Engl J Med; 2022 Feb; 386(5):449-462. PubMed ID: 35108470
[TBL] [Abstract][Full Text] [Related]
29. Nivolumab plus ipilimumab versus sunitinib in previously untreated advanced renal-cell carcinoma: analysis of Japanese patients in CheckMate 214 with extended follow-up.
Tomita Y; Kondo T; Kimura G; Inoue T; Wakumoto Y; Yao M; Sugiyama T; Oya M; Fujii Y; Obara W; Motzer RJ; Uemura H
Jpn J Clin Oncol; 2020 Jan; 50(1):12-19. PubMed ID: 31633185
[TBL] [Abstract][Full Text] [Related]
30. Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial.
Motzer RJ; Escudier B; McDermott DF; Arén Frontera O; Melichar B; Powles T; Donskov F; Plimack ER; Barthélémy P; Hammers HJ; George S; Grünwald V; Porta C; Neiman V; Ravaud A; Choueiri TK; Rini BI; Salman P; Kollmannsberger CK; Tykodi SS; Grimm MO; Gurney H; Leibowitz-Amit R; Geertsen PF; Amin A; Tomita Y; McHenry MB; Saggi SS; Tannir NM
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32661118
[TBL] [Abstract][Full Text] [Related]
31. Nivolumab in gastric/gastroesophageal junction cancer: real-world data from UK Early Access to Medicines Scheme.
Soni M; Kiff C; Carroll R; Stein D; Saragoussi D; Nassar A; Maisey N; Tyas D
Future Oncol; 2021 Aug; 17(24):3163-3174. PubMed ID: 34098737
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of PD-1 Inhibitors in First-Line Treatment for Advanced Gastroesophageal Junction and Gastric Cancer by Subgroups: A Systematic Review and Meta-Analysis.
Fei S; Lu Y; Chen J; Qi J; Wu W; Wang B; Han Y; Wang K; Han X; Zhou H; Wang J; Chen J
Chemotherapy; 2023; 68(4):197-209. PubMed ID: 37331333
[TBL] [Abstract][Full Text] [Related]
33. A matching-adjusted indirect comparison of combination nivolumab plus ipilimumab with BRAF plus MEK inhibitors for the treatment of BRAF-mutant advanced melanoma
Tarhini AA; Toor K; Chan K; McDermott DF; Mohr P; Larkin J; Hodi FS; Lee CH; Rizzo JI; Johnson H; Moshyk A; Rao S; Kotapati S; Atkins MB
ESMO Open; 2021 Apr; 6(2):100050. PubMed ID: 33556898
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial.
Shitara K; Van Cutsem E; Bang YJ; Fuchs C; Wyrwicz L; Lee KW; Kudaba I; Garrido M; Chung HC; Lee J; Castro HR; Mansoor W; Braghiroli MI; Karaseva N; Caglevic C; Villanueva L; Goekkurt E; Satake H; Enzinger P; Alsina M; Benson A; Chao J; Ko AH; Wainberg ZA; Kher U; Shah S; Kang SP; Tabernero J
JAMA Oncol; 2020 Oct; 6(10):1571-1580. PubMed ID: 32880601
[TBL] [Abstract][Full Text] [Related]
35. Quality of life with first-line pembrolizumab for PD-L1-positive advanced gastric/gastroesophageal junction adenocarcinoma: results from the randomised phase III KEYNOTE-062 study.
Van Cutsem E; Valderrama A; Bang YJ; Fuchs CS; Shitara K; Janjigian YY; Qin S; Larson TG; Shankaran V; Stein S; Norquist JM; Kher U; Shah S; Alsina M
ESMO Open; 2021 Aug; 6(4):100189. PubMed ID: 34371381
[TBL] [Abstract][Full Text] [Related]
36. A Q-TWiST Analysis Comparing Nivolumab and Therapy of Investigator's Choice in Patients with Recurrent/Metastatic Platinum-Refractory Squamous Cell Carcinoma of the Head and Neck.
Cocks K; Contente M; Simpson S; DeRosa M; Taylor FC; Shaw JW
Pharmacoeconomics; 2019 Aug; 37(8):1041-1047. PubMed ID: 30972702
[TBL] [Abstract][Full Text] [Related]
37. Oncological outcomes of addition of anti-PD1/PD-L1 to chemotherapy in the therapy of patients with advanced gastric or gastro-oesophageal junction cancer: A meta-analysis.
Zheng Z; Guo Y; Zou CP
Medicine (Baltimore); 2020 Feb; 99(7):e18332. PubMed ID: 32049776
[TBL] [Abstract][Full Text] [Related]
38. Low Programmed Death-Ligand 1-Expressing Subgroup Outcomes of First-Line Immune Checkpoint Inhibitors in Gastric or Esophageal Adenocarcinoma.
Zhao JJ; Yap DWT; Chan YH; Tan BKJ; Teo CB; Syn NL; Smyth EC; Soon YY; Sundar R
J Clin Oncol; 2022 Feb; 40(4):392-402. PubMed ID: 34860570
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of ramucirumab combination chemotherapy as second-line treatment in patients with advanced adenocarcinoma of the stomach or gastroesophageal junction after exposure to checkpoint inhibitors and chemotherapy as first-line therapy.
Masetti M; Al-Batran SE; Goetze TO; Thuss-Patience P; Knorrenschild JR; Goekkurt E; Folprecht G; Ettrich TJ; Lindig U; Luley KB; Pink D; Dechow T; Sookthai D; Junge S; Loose M; Pauligk C; Lorenzen S
Int J Cancer; 2024 Jun; 154(12):2142-2150. PubMed ID: 38447003
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]